Quinoline derivatives as glucokinase ligands

Details Quinoline derivatives as glucokinase ligands Quinoline derivatives as glucokinase ligands

2007-06-12

2007-06-12

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S314000

Reexamination Certificate

active

10534651

ABSTRACT:
Compounds of formula (I), wherein one of R1and R2is selected from a group (IA), ring A is substituted pyridin-z-yl of thiazol-z-yl, the other substituents are as described in the description and their use in the treatment or prevention of a disease or medical conditions mediated through glucokinase

REFERENCES:
patent: 4146631 (1979-03-01), Ford et al.
patent: 6448399 (2002-09-01), Corbett et al.
patent: 6545155 (2003-04-01), Corbett et al.
patent: 6613942 (2003-09-01), Ling et al.
patent: 2004/0214868 (2004-10-01), Hayter et al.
patent: 2005/0054715 (2005-03-01), Hayter et al.
patent: 2005/0080106 (2005-04-01), Boyd et al.
patent: 2006/0058353 (2006-03-01), Mckerrecher et al.
patent: 1336607 (2003-08-01), None
patent: 1600442 (2005-11-01), None
patent: 2385328 (2003-08-01), None
patent: 08 173525 (1996-07-01), None
patent: 08 301760 (1996-11-01), None
patent: 09040557 (1997-02-01), None
patent: 2000086657 (2000-03-01), None
patent: WO-00/26202 (2000-05-01), None
patent: WO-00/26202 (2000-05-01), None
patent: WO-00/58293 (2000-10-01), None
patent: WO-00/58293 (2000-10-01), None
patent: WO 01/19788 (2001-03-01), None
patent: WO-01/20327 (2001-03-01), None
patent: WO-01/44216 (2001-06-01), None
patent: WO-01/83465 (2001-11-01), None
patent: WO-01/83478 (2001-11-01), None
patent: WO-01/85706 (2001-11-01), None
patent: WO-01/85707 (2001-11-01), None
patent: WO-02/00633 (2002-01-01), None
patent: WO-02/08209 (2002-01-01), None
patent: WO-02/14312 (2002-02-01), None
patent: WO 02/24682 (2002-03-01), None
patent: WO-02/24682 (2002-03-01), None
patent: WO-02/24682 (2002-03-01), None
patent: WO-02/46173 (2002-06-01), None
patent: WO-02/46173 (2002-06-01), None
patent: WO-02/48106 (2002-06-01), None
patent: WO-02/064545 (2002-08-01), None
patent: WO-03/000262 (2003-01-01), None
patent: WO-03/000267 (2003-01-01), None
patent: WO-03/015774 (2003-02-01), None
patent: WO-03/022856 (2003-03-01), None
patent: WO-03/028641 (2003-04-01), None
patent: WO-03/047626 (2003-06-01), None
patent: WO-03/048152 (2003-06-01), None
patent: WO-03/055482 (2003-07-01), None
patent: WO-03/080585 (2003-10-01), None
patent: WO-03/082838 (2003-10-01), None
patent: WO-03/082838 (2003-10-01), None
patent: WO-03/095438 (2003-11-01), None
patent: WO-03/097824 (2003-11-01), None
patent: WO-04/002481 (2004-01-01), None
patent: WO 2004/031179 (2004-04-01), None
patent: WO-04/045614 (2004-06-01), None
patent: WO-04/046139 (2004-06-01), None
patent: WO-04/050645 (2004-06-01), None
patent: WO-04/052869 (2004-06-01), None
patent: WO-04/063179 (2004-07-01), None
patent: WO-04/063194 (2004-07-01), None
patent: WO-04/072031 (2004-08-01), None
patent: WO-04/072066 (2004-08-01), None
patent: WO-04/076420 (2004-09-01), None
patent: WO-04/081001 (2004-09-01), None
patent: WO 2004/076420 (2004-09-01), None
patent: WO-04/110375 (2004-12-01), None
patent: WO-05/044801 (2005-05-01), None
patent: WO-05/049019 (2005-06-01), None
patent: WO-05/054200 (2005-06-01), None
patent: WO-05/054233 (2005-06-01), None
patent: WO-05/056530 (2005-06-01), None
patent: WO 2005/063738 (2005-07-01), None
patent: WO 2005/066145 (2005-07-01), None
patent: WO 2005/080359 (2005-09-01), None
patent: WO 2005/080360 (2005-09-01), None
patent: WO 2005/090332 (2005-09-01), None
patent: WO 2005/095417 (2005-10-01), None
patent: WO 2005/095418 (2005-10-01), None
patent: WO 2005/103021 (2005-11-01), None
patent: WO 2005/121110 (2005-12-01), None
patent: WO 2005/123132 (2005-12-01), None
patent: WO 2006/016174 (2006-02-01), None
patent: WO 2006/016178 (2006-02-01), None
patent: WO 2006/016194 (2006-02-01), None
patent: WO 2006/040527 (2006-04-01), None
patent: WO 2006/040528 (2006-04-01), None
patent: WO 2006/040529 (2006-04-01), None
Kar, “Cinchophen Analogues as Potential CNS Agents,” Journal of Pharmaceutical Sciences, American Pharmaceutical Association 72(9):1082-1084 (1983).
Mein, Database Crossfile Beilstein ′Online! Beilstein Institut Zur Foerderung Der Chemischen Wissenshaften, Database accession No. 6511458(BRN) XP002272206 abstract and Indian J. Chem. Sect., 25(9):886 (1986).
Kudri, “Enamine Product Listing,” Database Chemcats ′Online! Chemical Abstract Service, XP002272448 Order No. T0505-1260, T0504-9244 (2001).
Kennedy, “Interchim Intermediated,” Database Chemcats ′Online! Chemical Abstracts Service XP002272449 (2002).
Edmont et al., “Synthesis and evaluation of quinoline carboxyguanidines as antidiabetic agents,” Bioorganic & Medicinal Chemistry Letters 10(16):1831-1834 (2000).
Alvarez et al., “Evidence that Glucokinase Regulatory Protein is Expressed and Interacts with Glucokinase in Rat Brain,” Journal of Neurochemistry 80:45-53 (2002).
Alvarez et al., “Expression of the Glucagon-Like Peptide-1 Receptor Gene in Rat Brain,” Journal of Neurochemistry 66(3):920-927 (1996).
Bell et al., “Glucokinae Mutations, Insulin Secretion, and Diabetes Mellitus,” Annu. Rev. Physiol. 58:171-186 (1996).
Brocklehurst et al., “Stimulation of Hepatocyte Glucose Metabolism by Novel Small Molecule Glucokinase Activators,” Diabetes 53:535-541 (2004).
Caro et al., “Liver Glucokinase: Decreased Activity in Patients with Type II Diabetes,” Horm. Metab. Res. 27:19-22 (1995).
Christesen et al., “The Second Activating Glucokinase Mutation (A456V) Implications for Glucose Homeostasis and Diabetes Therapy,” Diabetes 51:1240-1246 (2002).
Corbett, “Track 3—Mastering Medicinal Chemistry: Applying Organic Chemistry to Biological Problems, Success Stories in Medicinal Chemistry,” Molecular Medicine Tri-Conference, Moscone West Convention Center, San Francisco California, Mar. 26, 2005—11:00-11:30 Glucokinase Activators: Discovery of Novel, Orally Active Glucse Lowering Agents, Mar. 24-26, 2004.
DeFronzo, “The Triumvirate: β-Cell, Muscle, Liver—A Collusion Responsible for NIDDM,” Diabetes 37:667-687 (1988).
Desai et al., “Phenotypic correction of Diabetic Mice by Adenovirus-Mediated Glucokinase Expression,” Diabetes 50:2287-2295 (2001).
Ferre et al., “Correction of Diabetic Alteractions by Glucokinase,” Proc. Natl. Acad. Sci. USA 93:7225-7230 (1996).
Froguel et al., “Familial Hyperglycemia Due to Mutations in Glucokinase—Definition of a Subtype of Diabetes Mellitus,” The New England Journal of Medicine 328(10):697-702 (1993).
Fujimoto et al., “Administration of D-Glucosamine into the Third Cerebroventricle Induced Feeding Accompanied by Hyperglycemia in Rats,” Life Sciences 37(26):2475-2482 (1985).
Glaser et al., “Familial Hyperinsulinism Caused by an Activating Glucokinase Mutation,” The New England Journal of Medicine 338(4):226-230 (1998).
Grimsby et al., “Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy,” Science 301:370-373 (2003).
Grimsby, “Glucokinase Activators—Potential Treatment for Type 2 Diabetes,” Roche—SMi Diabetes London UK pp. 28-29 (2002.
Kurata et al., “D-Glucose Suppression of Eating After Intra-Third Ventricle Infusion in Rat,” Physiology & Behavior 37:615-620 (1986).
Kurata et al., “Structural Evaluation of Glucose Analogues on Feeding Elicitation in Rat,” Metabolism 38(1):46-51 (1989).
Levin et al., “Brain Glucose Sensing and body Energy Homeostasis: Role in Obesity and Diabetes,” A.J. of Physiology 276:R1223-R1231 (1999).
Levin et al., “Differential Effects of Diet and Obesity on High and Low Affinity Sulfonylurea Binding Sites in the Rat Brain,” Brain Research 739:293-300 (1996).
Levin et al., “In vivo and In vitro Regulation of [3H] Glyburide Binding to Brain Sulfonylurea Receptors in Obesity-Prone and Resistant Rats by Glucose,” Brain Research 776:146-153 (1997).
Levin et al., “Reduced Glucose-Induced Neuronal Activation in the Hypothalamus of Diet-Induced Obese Rats,” Brain Research 808:317-319 (1998).
Levin,

Affiliated with

Also associated with

Rating

Quinoline derivatives as glucokinase ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinoline derivatives as glucokinase ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoline derivatives as glucokinase ligands will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3863256